Expression of cyclin A1 mRNA in patients with myelodysplastic syndrome and its clinical significance.
- Author:
Jin-Song JIA
1
;
Shi-Rong XU
Author Information
1. Institute of Hematology, Peking University People Hospital, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Case-Control Studies;
Cyclin A1;
genetics;
metabolism;
Female;
HL-60 Cells;
Humans;
K562 Cells;
Male;
Middle Aged;
Myelodysplastic Syndromes;
genetics;
metabolism;
RNA, Messenger;
genetics;
Reverse Transcriptase Polymerase Chain Reaction;
Young Adult
- From:
Journal of Experimental Hematology
2009;17(2):377-381
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to evaluate the expression of cyclin A1 mRNA in patients with myelodysplastic syndrome (MDS) and its clinical significance. The expression of cyclin A1, cdk2 and p21(cip1) mRNA in the bone marrow from 56 patients with MDS and 10 normal control were measured by using reverse transcription polymerase chain reaction (RT-PCR) technique. The results indicated that the positive rate and the expression level of cyclin A1 in MDS patients (69.64%; 0.964 +/- 1.879) were significantly higher than those in normal control (0%; 0.012 +/- 0.014) (p < 0.01). Among de-novo MDS patients, the expression level of cyclin A1 mRNA in the MDS-RAEB group (1.895 +/- 1.769) was higher than that in MDS-RA group (0.629 +/- 1.583) (p < 0.01). The expression level of cyclin A1 mRNA in post-treatment group was significantly lower than that in prior-treatment group (p < 0.01). It is concluded that the mRNA expression of cyclin A1 in MDS patients is higher than that in normal control, the abnormal expression of cyclin A1 may be used as a prognostic marker in MDS patients.
